Colorectal Cancer Report Summary
Incidence of Colorectal Cancer continues to rise, with the disease now ranked 3rd for prevalence amongst cancer indications and cases predicted to increase by 63% by 2040.
With exclusive data from Beacon, this report contains:
- Analysis of Colorectal Cancer assets advancing towards late-phase clinical trials
- Insights into promising novel targets across all drug modalities
- Overview of recent approvals in the Colorectal Cancer treatment landscape
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
